Morria Biopharmaceuticals Plc. Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a …
Morria Biopharmaceuticals Plc. Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a …
LONDON & NEW YORK—-Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the initiation of its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug MRX6.
Read more on Business Wire via Yahoo! Finance
Related posts:
- Provectus Reports on Successful End-of-Phase 2 Meeting with U.S. FDA and Gains Clarity for Licensure of PV-10 for …
- Celebrity Photographer Jeremy Kost Creates Images of Isolation to Empower Eczema Patients to Share Their Stories and Take Control
- Eczema Study Reveals Severe Emotional Effects on School Children
- Scalp Health Announces New Itchy Scalp Shampoo
- What is the difference between allergic contact dermatitis and irritant contact dermatitis?